KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zimmer Biomet Holdings (ZBH) EBITDA (2016 - 2025)

Zimmer Biomet Holdings has reported EBITDA over the past 17 years, most recently at $154.5 million for Q4 2025.

  • Quarterly results put EBITDA at $154.5 million for Q4 2025, down 60.28% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 14.59% YoY), and the annual figure for FY2025 was $1.1 billion, down 14.59%.
  • EBITDA for Q4 2025 was $154.5 million at Zimmer Biomet Holdings, down from $351.3 million in the prior quarter.
  • Over the last five years, EBITDA for ZBH hit a ceiling of $389.0 million in Q4 2024 and a floor of -$28.3 million in Q4 2022.
  • Median EBITDA over the past 5 years was $273.0 million (2023), compared with a mean of $247.9 million.
  • Peak annual rise in EBITDA hit 22144.44% in 2022, while the deepest fall reached 121.15% in 2022.
  • Zimmer Biomet Holdings' EBITDA stood at $133.8 million in 2021, then plummeted by 121.15% to -$28.3 million in 2022, then skyrocketed by 1351.59% to $354.2 million in 2023, then increased by 9.82% to $389.0 million in 2024, then plummeted by 60.28% to $154.5 million in 2025.
  • The last three reported values for EBITDA were $154.5 million (Q4 2025), $351.3 million (Q3 2025), and $300.0 million (Q2 2025) per Business Quant data.